MX2018012176A - Anticuerpos anti-factor bb del complemento y usos de estos. - Google Patents

Anticuerpos anti-factor bb del complemento y usos de estos.

Info

Publication number
MX2018012176A
MX2018012176A MX2018012176A MX2018012176A MX2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A MX 2018012176 A MX2018012176 A MX 2018012176A
Authority
MX
Mexico
Prior art keywords
antibodies
complement factor
complement
present disclosure
disclosure provides
Prior art date
Application number
MX2018012176A
Other languages
English (en)
Inventor
Panicker Sandip
Parry Graham
Sue Christopherson Karen
Sangyoung Byun Tony
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2018012176A publication Critical patent/MX2018012176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona anticuerpos anti-factor Bb del complemento y composiciones que comprenden los anticuerpos. Los anticuerpos anti-Bb son útiles para el tratamiento de trastornos mediados por el complemento. La presente descripción proporciona métodos para el tratamiento de trastornos mediados por el complemento.
MX2018012176A 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y usos de estos. MX2018012176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018012176A true MX2018012176A (es) 2019-02-07

Family

ID=60000646

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012176A MX2018012176A (es) 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y usos de estos.
MX2023007149A MX2023007149A (es) 2016-04-04 2018-10-04 Anticuerpos anti-factor bb del complemento y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007149A MX2023007149A (es) 2016-04-04 2018-10-04 Anticuerpos anti-factor bb del complemento y usos de estos.

Country Status (23)

Country Link
US (3) US10934347B2 (es)
EP (1) EP3452510A4 (es)
JP (3) JP6967528B2 (es)
KR (2) KR20240096672A (es)
CN (2) CN116790614A (es)
AU (1) AU2017246794B2 (es)
BR (1) BR112018070357A2 (es)
CA (1) CA3019332A1 (es)
CL (1) CL2018002810A1 (es)
CO (1) CO2018010827A2 (es)
CR (1) CR20180529A (es)
DO (1) DOP2018000219A (es)
EA (1) EA201892225A1 (es)
EC (1) ECSP18082302A (es)
IL (3) IL262010B (es)
MA (1) MA44878A (es)
MX (2) MX2018012176A (es)
MY (1) MY194603A (es)
PE (1) PE20190209A1 (es)
PH (1) PH12018502137A1 (es)
SG (1) SG11201808525UA (es)
TN (1) TN2018000341A1 (es)
WO (1) WO2017176651A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013002074B1 (pt) 2010-07-28 2021-09-14 Gliknik Inc Composto homodimérico, dímero ou multímero de ordem superior do composto homodimérico, composição, composto, multímero e usos dos mesmos
IL262010B (en) 2016-04-04 2022-09-01 Bioverativ Usa Inc Anti-complement factor bb antibodies and their uses
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
IL266988B1 (en) 2016-12-09 2024-07-01 Gliknik Inc Methods for the treatment of inflammatory disorders with multivalent FC compounds
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
US11905533B2 (en) 2017-12-19 2024-02-20 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
BR112021026181A2 (pt) * 2019-06-27 2022-02-15 Verseau Therapeutics Inc Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos
WO2021011903A1 (en) * 2019-07-17 2021-01-21 Gemini Therapeutics Inc. Factor h potentiating antibodies and uses thereof
US20230050339A1 (en) * 2020-02-18 2023-02-16 Children's Hospital Medical Center Compositions and methods for treating liver disease
CN115702165A (zh) * 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1996017951A2 (en) 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
WO1996019487A1 (fr) 1994-12-22 1996-06-27 Nissan Chemical Industries, Ltd. Derives d'organobismuth et procede de production
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
KR20010015856A (ko) 1997-12-12 2001-02-26 마크로메드 인코퍼레이션 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜)
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP2340850A1 (en) 2004-02-10 2011-07-06 The Regents of the University of Colorado, a Body Corporate Inhibition of factor B, the alternative complement pathway and methods related thereto
CN102603895B (zh) 2004-06-18 2016-09-28 Ambrx公司 新颖抗原结合多肽和其用途
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007056227A2 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
DK2532681T3 (en) 2005-12-20 2015-01-05 Sbi Biotech Co Ltd Anti-ILT7 antibody
WO2009029669A1 (en) * 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
MX2010005115A (es) * 2007-11-08 2010-05-27 Genentech Inc Anticuerpos anti-factor b y sus usos.
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CN103665170A (zh) 2008-12-05 2014-03-26 安吉奥开米公司 肽治疗剂轭合物及其应用
CA2776144C (en) * 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
CA2853719A1 (en) 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Humanized antibodies to inkt
PE20150090A1 (es) 2012-02-24 2015-02-16 Stem Centrx Inc Moduladores y metodos de empleo novedosos referencia cruzada a solicitudes
EP2834271B1 (en) 2012-04-03 2019-01-16 NovelMed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
US8945562B2 (en) * 2012-11-02 2015-02-03 True North Therapeutics, Inc. Anti-complement C1s antibodies
DK2958944T3 (da) 2013-02-22 2019-06-24 Abbvie Stemcentrx Llc Anti-dll3-antistof-pbd-konjugater og anvendelser deraf
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
WO2015051159A1 (en) 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2015130826A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. COMPLEMENT FACTOR Bb ANTIBODIES
SG10201913303XA (en) 2015-07-13 2020-03-30 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
IL262010B (en) 2016-04-04 2022-09-01 Bioverativ Usa Inc Anti-complement factor bb antibodies and their uses
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
CN115702165A (zh) 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途

Also Published As

Publication number Publication date
TN2018000341A1 (en) 2020-06-15
WO2017176651A1 (en) 2017-10-12
KR102673420B1 (ko) 2024-06-07
AU2017246794A1 (en) 2018-10-25
JP6967528B2 (ja) 2021-11-17
JP2021191789A (ja) 2021-12-16
IL295288B2 (en) 2024-08-01
CN109563158B (zh) 2022-08-09
CN109563158A (zh) 2019-04-02
MY194603A (en) 2022-12-06
CL2018002810A1 (es) 2019-03-15
ECSP18082302A (es) 2019-01-31
IL262010B (en) 2022-09-01
IL295288B1 (en) 2024-04-01
US10934347B2 (en) 2021-03-02
JP7326393B2 (ja) 2023-08-15
US20210221877A1 (en) 2021-07-22
CA3019332A1 (en) 2017-10-12
IL262010A (en) 2018-10-31
CR20180529A (es) 2019-03-21
IL295288A (en) 2022-10-01
MA44878A (fr) 2019-03-13
US11851482B2 (en) 2023-12-26
DOP2018000219A (es) 2019-03-31
JP2023139289A (ja) 2023-10-03
EP3452510A1 (en) 2019-03-13
MX2023007149A (es) 2023-06-28
EA201892225A1 (ru) 2019-09-30
PH12018502137A1 (en) 2019-09-23
CN116790614A (zh) 2023-09-22
US20190153079A1 (en) 2019-05-23
SG11201808525UA (en) 2018-10-30
AU2017246794B2 (en) 2024-07-04
IL311675A (en) 2024-05-01
EP3452510A4 (en) 2020-01-15
US20240228599A1 (en) 2024-07-11
JP2019513726A (ja) 2019-05-30
CO2018010827A2 (es) 2018-11-22
KR20240096672A (ko) 2024-06-26
KR20190003951A (ko) 2019-01-10
BR112018070357A2 (pt) 2019-01-29
PE20190209A1 (es) 2019-02-07

Similar Documents

Publication Publication Date Title
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
PH12019502283A1 (en) Anti-lag3 antibodies
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2022003273A (es) Anticuerpos anti-tau y metodos de uso.
MX2019007021A (es) Anticuerpos il-11ra.
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2019007020A (es) Anticuerpos il-11.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
SG10201809668TA (en) Anti-her2 antibodies and immunoconjugates
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2019007496A (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil.
PH12020550023A1 (en) Compositions for treating stress-related disorders
PH12017501864A1 (en) Compositions and methods for treating autism
TW201713686A (en) Methods for preparing modified von Willebrand factor
PH12019500479A1 (en) Compositions for treating dementia